Log In

Term Description

Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy. A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to control gene is less than or equal to 0.1% according to the International Scale (IS), a consensus standardized measurement scale intended to allow direct comparison of BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use. Studies have demonstrated that achieving MMR within 18 months following TKI therapy is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML, 2013).

LOINC Names Get Info

Fully-Specified Name
t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment:PrThr:Pt:Bld/Tiss:Ord:Molgen
Long Common Name
BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment
Short Name
t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql
Display Name
t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1% post treatment Molgen Ql (Bld/Tiss)
Consumer Name Alpha Get Info
t(9;22)(q34.1;q11)(ABL1,BCR) B2a2+b3a2/control Transcript.reduction to 0.1% - after Treatment, Blood or tissue specimen

Part Model Get Info

  • Component
    t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment
    LP308656-0
    • Analyte
      t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%
      LP287181-4
      • Component Numerator
        t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript
        LP229766-3
        • Component Numerator Core
          t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2
          LP150240-2
        • Component Numerator Core Suffix
          fusion transcript
          LP150217-0
      • Component Denominator
        control transcript.reduction to 0.1%
        LP173653-9
        • Component Denominator Core
          control transcript.reduction to 0.1%
          LP173653-9
        • Component Denominator Core Suffix
          NULL
           
    • Challenge
      post treatment
      LP93420-5
    • Adjustment
      NULL
       
    • Count
      NULL
       
  • Property
    PrThr
    LP217195-9
  • Time
    Pt
    LP6960-1
  • System
    Bld/Tiss
    LP7061-7
    • System Core
      Bld/Tiss
      LP7061-7
    • Super System
      NULL
       
  • Scale
    Ord
    LP7751-3
  • Method
    Molgen
    LP6404-0

Example Answer List: LL365-8

Source: HL7
Code System
HL7v2
Code System OID
2.16.840.1.113883.12.136
AnswerCodeScoreAnswer ID
YesCopyright http://snomed.info/sct ID:373066001 Yes (qualifier value)YLA33-6
NoCopyright http://snomed.info/sct ID:373067005 No (qualifier value)NLA32-8

Basic Attributes

Class
MOLPATH
Type
Laboratory
First Released
Version 2.46
Last Updated
Version 2.56 (MIN)
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation
Both

Language Variants Get Info

TagLanguageTranslation
cs-CZCzech (Czechia)Fúzní transkript t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2/kontrolní transkript.redukce na 0,1%^Po ošetření:Přítomnost nebo práh:Časový bod:Krev/tkáň:Ordinální:Molekulární genetika
el-GRGreek (Greece)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 μεταγραφή συγχώνευσης/μεταγραφή ελέγχου.μείωση στο 0,1%^κατόπιν θεραπείας:PrThr:Pt:Αίμα/Ιστός:Ord:Μοριακή γενετική
Synonyms: MOLPATH Ord PrThr Pt t(9;22)(q34.1;q11)(ABL1,BCR) t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 Αίμα Αίμα/Ιστός Ιστός κατόπιν θεραπείας μεταγραφή συγχώνευσης Μοριακή γενετική
es-ESSpanish (Spain)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 Tránscritos de fusión/control transcripción.reducción al 0,1%^Post tratamiento:PrThr:Punto temporal:Sangre o tejido:Ord:Genética molecular
es-MXSpanish (Mexico)t (9; 22) (q34.1; q11) (ABL1, BCR) transcripción de fusión b2a2 + b3a2 / transcripción de control reducción a 0.1%^ después del tratamiento:Presencia o umbral:Punto temporal:Sangre o tejido:Ordinal:Genética molecular
fr-FRFrench (France)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcript de fusion/transcrit de référence réduction à 0.1%^après traitement:Présence/Seuil:Ponctuel:Sang/Tissu:Qualitatif:Biologie moléculaire
fr-CAFrench (Canada)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcrit de fusion/Transcrit de contrôle. Réduction à 0,1%^post traitement:Présence-Seuil:Temps ponctuel:Sang/Tissu:Ordinal:Molgen
it-ITItalian (Italy)t(9,22)(q34.1,q11)(ABL1,BCR) b2a2+b3a2, trascritto di fusione/Trascrizione di controllo.riduzione al 0.1%^post trattamento:PrThr:Pt:Sangue/Tess:Ord:Molgen
Synonyms: dopo trattamento Genetica molecolare Patologia molecolare Presenza o Soglia Punto nel tempo (episodio) Sangue Sangue o Tessuto Tessuto & Strisci
pl-PLPolish (Poland)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transkrypt fuzyjny/transkrypt kontrolny, Redukcja do 0,1%^po leczeniu:granica wykrywalności:punkt w czasie:krew lub tkanka:uporządkowany:genetyka molekularna
Synonyms: diagnostyka molekularna
pt-BRPortuguese (Brazil)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcrição de fusão/controle de transcrição para 0.1%^pos tratamento:Limiar:Pt:Sg/Tecido:Ord:Genética molecular
ru-RURussian (Russian Federation)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 слияния транскрипт/контрольный транскрипт.редукция до 0.1%^после лечения:PrThr:ТчкВрм:Кр/Тк:Пор:МолГен
Synonyms: Кровь Кровь или Ткань Порядковый Ткань и мазки Точка во времени;Момент химерная РНК, закодированная слитым геном
tr-TRTurkish (Turkey)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 füzyon transkript/kontrol transkript.%0.1'e düşürme^tedavi snr:MevcEşik:Zmlı:Kan/Dk:Srl:Molgen
Synonyms: Mevcut
zh-CNChinese (China)t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 融合转录物/对照转录物.降低至 0.1%^在治疗之后:存在情况或阈值:时间点:全血/组织:序数型:分子遗传学类实验室方法
Synonyms: ABL CML JTK7 p150 v-abl Abelson murine leukemia viral oncogene homolog 1 v-abl Abelson 小鼠白血病病毒癌基因同源体 1 v-abl Abelson 小鼠白血病病毒肿瘤基因同源体 1 v-abl Abelson 小鼠白血病病毒致癌基因同源体 1 v-abl Abelson 鼠科动物白血病病毒致癌基因同源体 1 v-abl Abelson 鼠科白血病病毒致癌基因同源体 1 XXX刺激 - 在...之后 之后于... 之后于治疗;在处理之后 依次型;分类顺序型;定性的;序数型（或称等级型）;性质上的;有序型;有序性分类应答;有序性分类结果;秩次型;等级型;筛查;顺序型 全血或组织;血液/组织;血液或组织 分子病理学;分子病理学试验 分子遗传学;分子遗传学方法;分子遗传学类方法;分子遗传学类检验方法;包括 RFL、PCR 及其他方法在内，用于在分子基础上检测遗传属性的方法的大类;聚合酶链反应;聚合酶链式反应 在...以后 在后 存在情况;存在;存在与否;是否存在;阈值;界值;界限;阀值;临界值;存在情况（存在、存在与否、是否存在）或阈值（界值、界限、阀值、临界值） 慢性粒细胞性白血病 慢性粒细胞白血病 慢性粒细胞白血病（Chronic myeloid leukemia，CML） 慢性髓系白血病 断点簇集区 断裂点丛集区 断裂点簇集区 断裂点聚集区 断裂点集中区 断裂点集中区（Breakpoint cluster region，BCR） 时刻;随机;随意;瞬间 易位(9;22)(q34.1;q11)(ABL1,BCR) 易位(9;22)(q34.1;q11)(ABL1,BCR) b2a2 易位(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 未作说明的组织;组织;组织 & 涂片 融合转录物（转录本、转录产物、转录子、转录）;融合基因转录本;融合转录 血;血液 限制性断裂区

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=74041-5